Detailed dose evidence documented for Icatibant in its monograph — reference only, not dosing recommendations.
Reference only — not a dosing recommendation.
Approved regimen
Approved labeled regimen
Product-, indication-, and jurisdiction-specific — see the monograph
Adults: 30 mg SC injection in the abdominal area. If response inadequate or symptoms recur: additional 30 mg doses at ≥6 h intervals. Maximum: 3 doses in 24 h. Patients may self-administer upon attack recognition.
Studied in trials
Studied regimens (not recommendations)
Studied in trials — not a recommended dose
Repeat dosing studied in open-label extension (up to 3 doses/24 h); longer-term safety data from registry studies.
Not established
What is not established
Safety and efficacy in pediatric patients <18 years (not established).
Use during pregnancy (limited human data; animal studies show no teratogenicity).
Dosing in renal or hepatic impairment (not formally studied; no label adjustment).